


In the Claims

Please amend the claims presented during the international phase as follows.

Applicant presents a full set of claims showing markups of the claims with insertions and deletions indicated by underlining (or double bracketing) and strikethrough text, respectively.

1. (Original) A pharmaceutical composition (excluding smoked cannabis) comprising at least one compound of the general formula 1

Formula 1



where;

R¹ is OH;

R² is H or COOH;

R³ is C₁-C₈ alkyl group;

and R⁴ is H

or a derivative thereof for use in treating mood disorders.

2. (Original) A pharmaceutical composition as claimed in claim 1 wherein R³ is a C1-C5 alkyl group.
3. (Original) A pharmaceutical composition as claimed in claim 1 wherein R³ is a C3-C5 alkyl group.
4. (Currently amended) A pharmaceutical composition as claimed in claim 1 ~~any one of claims 1 to 3~~ wherein R³ is a straight chain alkyl group.
5. (Original) A pharmaceutical composition as claimed in claim 1 wherein R³ is C₅H₁₁.

6. (Original) A pharmaceutical composition as claimed in claim 1 wherein R³ is C₃H₇.
7. (Currently amended) A pharmaceutical composition as claimed in claim 1 ~~any of the preceding claims~~, which comprises an extract of one or more cannabis plants.
8. (Original) A pharmaceutical composition as claimed in claim 7 wherein the extract comprises substantially all the naturally occurring cannabinoids in said plant(s).
9. (Original) A pharmaceutical composition as claimed in claim 1 which comprises an extract of one or more cannabis plants, which extract is enriched for cannabichromene.
10. (Currently amended) A pharmaceutical composition as claimed in claim 1 ~~any of claims 1 to 4~~ which comprises, as the active pharmaceutical agent, an isolated and substantially pure preparation of a compound according to formula 1.
11. (Currently amended) A pharmaceutical composition as claimed in claim 1 ~~any of the preceding claims~~ which is formulated for delivery nasally, sublingually, buccally, topically, orally, rectally, intravenously, intra-peritoneally, intra-muscularly, subcutaneously, transdermally, intra-vaginally, intra-urethrally ~~urethrally~~, by nebuliser, as inhaled vapour or by installation directly into the bladder.
12. (Currently amended) A pharmaceutical composition as claimed in claim 1 ~~any of the preceding claims~~ wherein said composition comprises, in addition to the at least one compound of the general formula 1 ~~pharmaceutically active ingredient~~, one or more pharmaceutically acceptable diluents, excipients or carriers.
13. (Currently amended) A pharmaceutical composition as claimed in claim 1 ~~any of the preceding claims~~ for use in the treatment of morbid or clinical depression, unipolar mood disorder, bipolar mood disorder, syndromal depression, panic disorder or anxiety.
14. (Currently amended) A method of treating a mood disorder in a human patient, which comprises administering to a patient in need thereof a therapeutically effective amount of a

compound of Formula 1 as defined in claim 1 or a pharmaceutical composition according to claim 1 ~~any one of claims 1 to 13.~~

15. (Currently amended) The method ~~Method~~ according to claim 14 wherein the mood disorder is morbid or clinical depression, unipolar mood disorder, bipolar mood disorder, syndromal depression, panic disorder or anxiety.

16.-17. (Canceled)

18. (Currently amended) The method according to claim 14 ~~Use according to claim 16 or claim 17~~ wherein the compound of formula 1 is present in an extract of at least one cannabis plant.

19. (New) The method according to claim 14, wherein the compound or the composition is administered nasally, sublingually, buccally, topically, orally, rectally, intravenously, intra-peritoneally, intra-muscularly, subcutaneously, transdermally, intra-vaginally, intra-urethrally, by nebuliser, as inhaled vapour or by installation directly into the bladder.